A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the March 7 2013 issue of Nature by Prof Dimmler, Boon, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small RNA-based therapy for Myocardial Infarction: p53 homolouge, p63 improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10). By increasing the expression of p63 in cardiomyocytes, one may prevent ageing-associated decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “p63 or its activators” may be used to improve cardiac function after myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Small RNA-based therapy for Myocardial Infarction: p53 homolouge, p63 improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 15/September/2014, 06.55 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
